CytomX Therapeutics, Inc. · NASDAQ:CTMX
CytomX Therapeutics — Investor Presentation (January 2017)
27 slides from CytomX Therapeutics's investor presentation, Jan 10, 2017
Slide 1: Reinventing Therapeutic Antibodies for Cancer
REINVENTING THERAPEUTIC ANTIBODIES FOR CANCER January 10, 2017 © 2017 CytomX Therapeutics, Inc. Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding
Slide 3: Goals in Clinical Oncology Today
Goals in Clinical Oncology Today % Survival Time SOC Chemo/TKI IO Monotherapy Ipi/nivo Combo Next Wave of Combos and Innovation é Response (particularly CR) ê Toxicity Durability of response Survival Options for PD-(L)1 progressors Important Progress in Last Five Years; Still Much Room for Improveme
Slide 4: Reinventing Therapeutic Antibodies for Cancer
Reinventing Therapeutic Antibodies for Cancer Innovative antibody platform designed to enhance tumor targeting and create or widen therapeutic window Built on deep scientific know-how, more than a decade of scientific research and >150 CytomX-owned patents and patent applications PROBODY is a tradem
Slide 5: Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment
Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment ANTI-CANCER ANTIBODY LINKER MASKING PEPTIDE PROTEASES
Slide 6: Broad Probody Therapeutic Pipeline Poised for Proof of Concept and Value Creation
PRODUCT CANDIDATE DISCOVERY LEAD OPTIMIZATION IND-ENABLING PHASE 1 CX-072 CX-2009 CX-2029 CTLA-4 Probody Tx CX-188 T-cell Bispecifics Additional PDCs Immunotherapy Discovery Broad Probody Therapeutic Pipeline Poised for Proof of Concept and Value Creation PIPELINE CD166 PDC CD71 PDC PD-L1 CTLA-4 PD-
Slide 7: Immuno-Oncology Programs: CX-072 (Anti-PD-L1), CTLA-4
IMMUNO-ONCOLOGY PROGRAMS CX-072 (ANTI-PD-L1) CTLA-4
Slide 8: Full Potential for Combination Immunotherapy is Limited by Toxicities
Full Potential for Combination Immunotherapy is Limited by Toxicities *Treatment-related **Not reported 1. Larkin et al., NEJM, July 2015. 2. Chapman et, al. NEJM, 2011. 3. Hamid, Society for Melanoma Research 2015 Opdivo alone Yervoy Alone Yervoy + Opdivo1 ORR 44% 19% 58% Grade 3-4 AEs* 16% 27% 55%
Slide 9: Emerging Clinical Data: Increased Efficacy at the Cost of Increased Toxicity
*CytomX analysis of available data through ASCO and ESMO 2016 Emerging Clinical Data: Increased Efficacy at the Cost of Increased Toxicity* EFFICACY PD-(L)1 Agent SOC Agent Combo SAFETY PD-(L)1 Agent SOC Agent Combo CTLA-4 CHEMO IDO BRAF &/or MEK VEGF EGFR CTLA-4 CHEMO IDO BRAF &/or MEK VEGF EGFR Ov
Slide 10: Rationale for Probody Therapeutics in Immuno-Oncology
Rationale for Probody Therapeutics in Immuno-Oncology Studies indicate localizing immunotherapies to the tumor can achieve efficacy without toxicity1,2,3,4,5 Probody Therapeutics are designed to achieve localized effects with conventional administration 1. Marabelle, A., et. al., Clin Cancer Res; 19
Slide 11: CX-072 Has the Potential to Become the PD-L1 Combination Agent of Choice
CX-072 Has the Potential to Become the PD-L1 Combination Agent of Choice CX-072 PD-L1 PROBODY THERAPEUTIC Checkpoint Inhibitors Traditional Chemotherapy Other Cancer Immuno- therapies Kinase Inhibitors ADCs Validated target Well-established efficacy & safety for class
Slide 12: CX-072 Preclinical Proof of Concept
Non-binding Control Antibody Parent PD-L1 Antibody CX-072 PD-L1 Probody Tx Tumor CX-072 Preclinical Proof of Concept TUMOR GROWTH SAFETY Induction of Autoimmunity Prevents Binding in Periphery Autoimmunity Reduced Similar Efficacy Localizes to Tumor Tx
Slide 13: PROCLAIM-072 (PD-L1) Phase 1/2 Clinical Trial Design
PROCLAIM-072 (PD-L1) Phase 1/2 Clinical Trial Design ≤1 MPK CX-072 + 3 MPK IPI (concomitant & phased schedules) DOSE ESCALATION A: MONOTHERAPY DOSE ESCALATION All comers C: VEMURAFENIB COMBO B: IPILIMUMAB COMBO CX-072 + 960 MG VEM ENROLLMENT ENROLLMENT & FOLLOW UP
Slide 14: PROCLAIM-072 Patient Population
PROCLAIM-072 Patient Population CANCER TYPES PD-L1 STATUS PRIOR PD-1/PD-L1 EXPOSURE PART A: Monotherapy *Metastatic or locally advanced unresectable tumors and lymphomas Preferential enrollment for known PD-L1-positive patients No PART B: Ipi Concomitant Retrospective analysis PART B: Ipi Phased Yes
Slide 15: BMS Immuno-Oncology Collaboration Update
BMS Immuno-Oncology Collaboration Update 4 target collaboration (target 4 selected in December) CTLA-4/Yervoy: clinical candidate selected in December $75M in upfronts Tiered royalties reaching low teens $1.2B in potential milestones PD-L1, PD-1 and other validated IO targets carved out Invested $10
Slide 16: Probody Drug Conjugate Programs: CX-2009 (CD166), CX-2029 (CD71)
PROBODY DRUG CONJUGATE PROGRAMS CX-2009 (CD166) CX-2029 (CD71)
Slide 17: Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets
Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets PDC Targets May Have More Attractive Attributes: CD166 CD71 Her2 CD30 Mesothelin Folate Receptor CD166 PDC Targets ADC Targets ADC Targets are Limited Based on Healthy Tissue Expression: More patients More indications Sou
Slide 18: CX-2009 is Highly Active in Preclinical Tumor Models
CX-2009 is Highly Active in Preclinical Tumor Models IV dosing on days 0 and 7 Tumor regressions at expected clinical dose (5 mpk) CD166 IHC
Slide 19: CX-2009 Has Broad Potential Utility Across Tumor Types
Lung cancer Prostate cancer Other cancers Exploratory, non-GLP toxicology study with necropsy and histopath demonstrated therapeutic window GLP toxicology complete Drug product manufactured IND preparation underway (1H’17 filing) CX-2009 Has Broad Potential Utility Across Tumor Types Ovarian cancer
Slide 20: CX-2009 (CD166): Clinical Strategy
2H17 – 2018: Launch Phase I/II Study CX-2009 (CD166) CX-2009 (CD166): Clinical Strategy Monotherapy dose escalation Expand to multiple cancers 1H 2017 2H 1H 2018 2H File IND Report biomarker, safety and efficacy data
Slide 21: CD71 is a Highly Desirable Antibody Drug Conjugate Target
CD71 is a Highly Desirable Antibody Drug Conjugate Target Ubiquitously expressed on dividing, normal and malignant cells Mediates iron uptake required for cell division A professional internalizing protein: often used as a positive control in ADC experiments Expression in normal dividing cells prohi
Slide 22: CD71-Probody Drug Conjugate Preclinical Proof of Concept
CD71-Probody Drug Conjugate Preclinical Proof of Concept TUMOR GROWTH TOLERABILITY IN NON-HUMAN PRIMATES Toxicity Reduced Similar Efficacy Cell Line-Derived Xenograft IgG control ADC CD71-ADC CD71-PDC NCI-H292 (Lung) Status: Lead Optimization AbbVie licensed SGEN’s validated MMAE payload
Slide 23: te ak “=
a te ak “= cn CYTOMX THERAPEUTICS
Slide 24: Broad Probody Therapeutic Pipeline Poised for Proof of Concept and Value Creation
PRODUCT CANDIDATE DISCOVERY LEAD OPTIMIZATION IND-ENABLING PHASE 1 CX-072 CX-2009 CX-2029 CTLA-4 Probody Tx CX-188 T-cell Bispecifics Additional PDCs Immunotherapy Discovery Broad Probody Therapeutic Pipeline Poised for Proof of Concept and Value Creation PIPELINE CD166 PDC CD71 PDC PD-L1 CTLA-4 PD-
Slide 25: Experienced Leadership Team
Sean McCarthy, D.Phil., MBA President and CEO W. Michael Kavanaugh, M.D. Chief Scientific Officer Rachel Humphrey, M.D. Chief Medical Officer Bob Goeltz, CPA, MBA Chief Financial Officer Debanjan Ray, MBA SVP, Strategy and Corporate Development Cynthia Ladd, JD General Counsel Danielle Olander VP, H
Slide 26: Reinventing Therapeutics Antibodies for Cancer: 2017/2018 Milestones
Reinventing Therapeutics Antibodies for Cancer Innovative Probody Platform Advancing Pipeline Strong Partners Well Funded 2017/2018 Milestones Two CytomX-owned programs entering clinic in 2017 Enhanced tumor targeting Partnership progress and potential for new alliances Strong cash position to advan
Slide 27: CytomX Therapeutics
CYTOMX THERAPEUTICS
CytomX Therapeutics — Investor Presentation (January 2017) on 6ix